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Background. Patients on maintenance hemodialysis 
typically show a suboptimal immune response to hepatitis 
B (HB) virus vaccination compared to the non-uremic 
population. The aim or our study was the identification of 
factors implicated in the vaccine response of our 
hemodialysis patients. 
Methods. We studied prospectively 63 hemodialysis 
patients who were seronegative for HB (37 males, 26 
females). Their mean age was 62.2±11.28 years (range 35-
80) and hemodialysis. Duration 55.96±50.1 months (range 
6-225) fourteen of them (22.2%) were diabetics. Our 
patients followed a four-dose vaccination schedule (0, 1, 2 
and 6 months) with 40 μg of a recombinant DNA HB 
vaccine. The antibody response was determined 1 month 
after the fourth dose of vaccination by assessing the titre of 
antiHBs antibodies (ab). Immune response was defined as 
sufficient when the antiHBs ab level was ≥ 12 mIU/ml. 
During the 6-month vaccination period we also monitored 
monthly and time-averaged Kt/V, residual renal function 
(RRF), BMI, serum creatinine, albumin, transferrin, ferritin, 
CRP, iPTH and the dose of erythropoietin and Vitamin D 
that they received. 
Results. An optimal immune response was achieved in 34 
patients (54%, responders) (antiHBs: 295.95±341.67 
mIU/ml), whereas 29 patients (46%, non-responders) 
showed a suboptimal response (antiHBs: 1.98±2.92 
mIU/ml) (p=1.75x10-5). There was a statistically significant 
negative correlation between the antiHBs ab titre and BMI 
(r=-0.28, p=0.024). A significant difference was also found 
between the BMI of responders and non-responders as 
groups (24.8±5.5 vs. 27.2±4.5, p=0.02). Grouping our 
patients according to the existence of diabetes, age (cut off 
60 years), and hemodialysis efficiency (Kt/V≥1.2) we 
found a statistically significant difference in the antiHBs ab 
titre between diabetics and non-diabetics (8.43±12.3 vs. 
200.2±317.7 mIU/ml, p=0.03), younger and older patients 
(262±365.09 vs. 84.36±189.1 mIU/ml, p=0.0145) and patients 
with efficient and inefficient hemodialysis (234.71±337.1 vs. 
79.14±200.99 mIU/ml, p=0.032). Treatment with vitamin D 
analogues, RRF and hypoalbuminemia were not found to be 
implicated in the immune response of our patients. 
Conclusions. It seems that increased BMI; diabetes; 
advanced age and inefficient hemodialysis impaired the 
immune response to HBV vaccination of our hemodialysis 
population. Future studies should be conducted to 
investigate the need for tailored vaccination schedules for 
this hemodialysis subpopulations. 
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Patients on maintenance hemodialysis are at high risk of 
infection with hepatitis B virus (HBV) despite segregation, 
universal precautions, vigorous vaccination protocols and 
the widespread use of erythropoetin leading to the reduced 
need for blood transfusions. At the same time hemodialysis 
patients typically show a suboptimal immune response to 
HB virus vaccination compared to the non-uremic popu-
lation  [1]. Protective antibody levels develop only in 60% 
of the hemodialysis population [2,3]. Many factors may be 
implicated in this suboptimal immune response such as 
uremia per se, altered renal metabolism of immunological 
active protein, the specific effect of renal replacement 
therapy, malnutrition, chronic inflammation, inefficient 
dialysis, age, race, diabetes mellitus and many more [4-15]. 
Moreover factors like insufficient vaccine dosing or omitting a 
dose may lead to suboptimal antibody production in 
hemodialysis patients [2-16]. In this context the aim or our 
study was the identification of factors implicated in the vaccine 
response of our hemodialysis population. 
 
Patients and methods 
From a cohort of 112 hemodialysis patients from our unit 
we studied prospectively 63 who were seronegative for HB 
(37 males, 26 females). An unsuccessful attempt for 
vaccination for HB was performed in 21 of the 63 patients 
included in the study. Positive patients for hepatitis B 
(HBeAg and anti-HBc) and those with a sufficient anti-HBs 
titer from former anti-HB vaccination, acute inflammatory 
status, malignancy and decompensated chronic liver disease 
were excluded. In addition, patients with autoimmune 
disease and patients which received immuno-suppressants 
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in the last three months were also excluded. The prevalence 
of hepatitis B and hepatitis C infection in unit is 2.67% (3 
patients) and 7,15% (8 patients) respectively. The 
demographic and laboratory characteristics of our study 
population are shown in Table 1. 
The laboratory values are the mean value of the six months 
observation period. The Mean age of our patients was 
62.2±11.28 years (range 35-80) and hemodialysis duration 
5.96±50.1 months (range 6-225). Fourteen (22.2%) of our 
patients were diabetics. Our patients followed a four-dose 
vaccination schedule with 40 μg of a recombinant DNA HB 
vaccine administered by deltoid intramuscular injection at 
time 0, 1, 2 and 6 months. We chose to use this vaccination 
schedule recommended by the U.S. Food and Drug 
Administration for Preventing Transmission of Infections 
Among Chronic Hemodialysis Patients because of the higher 
protective antibody response obtained (86%) in correlation 
with the three dose schedule (64%) recommended by the 
European best practice Guidelines [17,18]. 
 
Table 1. Demographic and laboratory characteristics of our 
hemodialysis patients 
Parameters Values 
Patients Number 63 
Males 37 
Females 26 
Male/Female ration 1.42 
Age (years) 62.2±11.28 
Time on HD* (months) 55.96±50.1 
Diabetics n=14 (22.2%) 
Time-averaged Kt/V 1.56±1.08 
RRF* (ml/min) 5.41±5.36 
BMI* (kg/m2) 26.03±4.13 
Serum creatinine (mg/dl) 9.53±2.48 
Serum albumin (g/L) 3.47±0.44 
Serum transferrin (g/L) 1.81±0.53 
Serum ferritin (mg/dl) 675.92±511.84 
CRP* (mg/dl) 1.05±1.41 
iPTH* (pg/ml) 187.21±171.31 
Erythropoietin dose (IU/week) 4790±3450 
* HD: hemodialysis, RRF: residual renal function, BMI: 




  The antibody response was determined 1 month after the 
fourth dose of vaccination by assessing the titre of antiHBs 
antibodies (ab). AntiHBs titers were measured in plasma 
samples by enzyme immuneassay (Abbott Laboratories 
USA). The immune response was defined as sufficient 
when the antiHBs ab level was ≥12 mIU/ml. Those with 
levels 12-100 mIU/ml were termed “poor responders”, 
whereas those with levels >100 mIU/ml were termed “good 
responders”. During the 6-month vaccination period we 
also monitored monthly time-averaged Kt/V, residual renal 
function (RRF), BMI, serum creatinine, albumin, 
transferrin, ferritin, CRP, iPTH and the dose of 




Results are reported as mean ± SD. Statistical significance 
was calculated for differences between means by use of an 
unpaired t-test. Correlation between variables was 
performed by the Pearson correlation test. A P value of less 




 An optimal immune response was achieved in 34 patients 
(54%, responders) (antiHBs: 295.95±341.67 mIU/ml), 
whereas 29 patients (46%, non-responders) showed a 
suboptimal response (antiHBs: 1.98±2.92 mIU/ml) 
(p=1.75x10-5). In the responder group 20 patients (59%) 
had an antibody titre of antiHBs > 100mIU/ml (good 
responders) and 14 patients (41%) had an antibody titre of 
antiHBs 12-100mIU/ml (poor response). There was a 
statistically significant negative correlation between the 
antiHBs ab titre and BMI (r=-0.28, p=0.024). A significant 
difference was also found between the BMI of responders 
and non-responders as groups (24.8±5.5 vs. 27.2±4.5, 
p=0.02). (Figure 1).  
 
Fig. 1. Difference of BMI between responders and non-responders 
 
 
Grouping our patients according to the existence of 
diabetes, age (cut off 60 years), and hemodialysis efficiency 
(Kt/V≥1.2) we found a statistically significant difference in 
the antiHBs ab titre between diabetics and non-diabetics 
(8.43±12.3 vs. 200.2±317.7 mIU/ml, p=0.03) younger and 
older patients (262±365.09 vs. 84.36±189.1 mIU/ml, 
p=0.0145) and patients with efficient and inefficient 
hemodialysis (234.71±337.1 vs. 79.14±200.99 mIU/ml, 
p=0.032) (Table 2). Treatment with vitamin D analogues, 
RRF and serum levels of creatinine, albumin, transferrin, 
ferritin, CRP and iPTH were not found to be implicated in 
the immune response of our patients. 
 
Table 2. Differences in the antibody response according to 
the existence of diabetes mellitus, age and hemodialysis 
efficiency in our hemodialysis patients 
Parameters HBsAb (mIU/ml) P 
Diabetics 8.43 
Non-diabetics 200.2 0.03 
Age < 60 years 262 
Age > 60 years 84.36 
0.0135 
Kt/V < 1.2 79.14 

























In our series, the percentage of patients responding to the 
HB vaccine was 54% which is similar to the results 
obtained in other groups [2,3]. This percentage is lower 
than in the general population despite using a double 
vaccination dose, reflecting the immune deficiency of 
patients with chronic renal failure. Many factors impinge on 
the effectiveness of a vaccine. Not only the potency of the 
vaccine is important, but also patient characteristics. Along 
with uremia, malnutrition, obesity, diabetes mellitus, 
increased age, seropositivity for antibody against hepatitis 
C, impaired T-cell receptor expression and HLA DR3, 
DR7, DQ2 have been associated with poor response of 
hemodialysis patients to HBV vaccine [2-12,14,15]. 
Conversely, there is evidence that Epo therapy improves 
response rates [13]. But it is worth mentioning that there is 
great controversy in the literature about the factors which 
are implicated in the antibody response of the hemodialysis 
population. 
In our study we found a better antibody response in the 
group with lower BMI. In one study Chow KM et al found 
an inadequate anti HBs response in obese hemodialysis 
patients, which could in part be attributed to a low vaccine 
dose, so it could be assumed that obese patients are in need 
of an even higher vaccine dose or maybe the dose should be 
calculated according to body weight [2]. 
We also found a better antibody response in the non-
diabetic group, consistent with the findings of the previous 
study [2]. However another study of Eardley et al did not 
confirm this finding in this paper the existence of diabetes 
mellitus did not affect response rates to the HB vaccine in 
hemodialysis patients [8]. We also found that patients in the 
younger age-group had a better respond rate to the 
vaccination schedule than our older patients, the same 
finding was also previously reported by other studies 
[2,5,9,12]. However other studies did not confirm an 
association between age and antibody response to the HB 
vaccine in HDpts [8,11]. Our study showed also a better 
immune response to vaccination in patients with higher 
Kt/V consistent with the findings of Kovacic V et al and 
Ibrahim S et al [10,11], a finding not confirmed by other 
studies [8,9,12]. 
Despite the limitations of the present study, that is the 
limited number of patients and the heterogeneous study 
population, as there was an attempt for vaccination against 
HBV in some of our patients in the past, our findings are of 
clinical relevance as some of the factors influencing the 
antibody response could be modifiable. So maybe there is need 
for a dose adjustment of the vaccine dose according to body 
weight in patients with a high BMI and diabetes mellitus. 
Another option is to vaccinate our patients at an early stage of 
chronic kidney disease before dialysis is started in an attempt 
to achieve a better antibody response at a younger age. 
Moreover optimizing the hemodialysis dose could also lead 




In conclusion, it seems that increased BMI; diabetes 
mellitus; advanced age and inefficient hemodialysis 
impaired the immune response to HBV vaccination of our 
haemodialysis population. However since there is great 
controversy in the literature about the factors which are 
implicated in the antibody response of hemodialysis 
patients it seems that there is need of a systemic review of 
the literature and meta-analysis of clinical trials, moreover 
future studies should be conducted to investigate the need 
for tailored vaccination schedules for specific hemodialysis 
subpopulations. 
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